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Summary 
Preliminary studies of the biochemical basis for the antiviral activity of the pyr- 
rolo[2,3-dlpyrimidine nucleoside ara-tubercidin were conducted. Herpes simplex 
virus DNA synthesis was 3-fold more sensitive to inhibition by ara-tubercidin than 
was cellular DNA synthesis. Partially purified herpes DNA polymerases were more 
sensitive to inhibition by ara-tubercidin S-triphosphate than were cellular poly- 
merases Q and p. Inhibition of viral DNA polymerase was competitive with dATP 
and noncompetitive with dTTP. The results suggest that the viral DNA polymer- 
ase plays a significant role in the antiviral activity of ara-tubercidin. 
Antiviral; Herpes, HSV; Nucleoside; Pyrrolopyrimidine; Ara-tubercidin 
The pyrrolo[2,3-d]pyrimidine nucleosides are purine nucleoside analogs in which 
the nitrogen atom at position 7 of the heterocyclic base has been replaced by a 
carbon atom. In addition to possessing antineoplastic, antimicrobial, and antipar- 
asitic activity (Ritch and Glazer, 1984), some of these compounds exhibit activity 
against a variety of RNA and DNA viruses. For example, tubercidin (Fig. l), was 
shown by Acs et al. (1964) to inhibit the in vitro replication of vaccinia virus, reo- 
virus, and mengovirus (a strain of murine encephalomyocarditis virus). The 5- 
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Fig. 1. Structure of (a) tubercidin (R = ribose) and (b) amtubercidin (R = arabinose). 
bromo derivative of tubercidin is an inhibitor of SV-40 and Rous sarcoma virus 
replication (Brdar et al., 1973). More recently, a larger series of 5substituted tub- 
ercidin analogs was found to possess activity against numerous viruses, including 
rhinoviruses (De Clercq et al., 1986) and herpes simplex virus types 1 and 2 (HSV- 
1 and HSV-2) (Bergstrom et al., 1984). Although tubercidin and other ribosyl pyr- 
rolopyrimidines effectively block virus replication, their associated cytotoxicity 
(Owen and Smith, 1964; Ritch and Glazer 1984; Suhadolnik, 1979) is far too great 
to permit consideration of these analogs as useful antiviral agents. 
In contrast, pyrrolopyrimidine nucleosides containing sugars other than ribose 
have exhibited improved antiviral selectivity against herpes viruses. The carbo- 
cyclic analogs of arabinosyl and lyxosyl 7-deazaguanine, for example, were active 
against HSV-1 and HSV-2 at concentrations lower than those necessary to pro- 
duce significant cytotoxicity (Legraverend et al., 1985; Zerial et al., 1986). Simi- 
larly, De Clercq and coworkers (De Clercq et al., 1987; De Clercq and Robins, 
1986) reported that xylotubercidin and other sugar-modified pyrrolopyrimidines 
possessed antiviral selectivity against HSV-1 and HSV-2 in vitro and in vivo. 
We recently reported that certain arabinosyl and deoxyribosyl pyrrolo[2,3-d]- 
pyrimidines are active and selective in vitro against both human cytomegalovirus 
(HCMV) and HSV-1 (Turk et al., 1987) Ara-sangivamycin, for example, pro- 
duced three- and five-logarithmic reductions in HSV-1 and HCMV titers, respec- 
tively, at a concentration (10 FM) approximating the 50% inhibitory (I& concen- 
tration for cellular cytotoxicity. We further found that viral DNA replication was 
inhibited by these compounds and hypothesized that this inhibition formed the ba- 
sis for antiviral activity. In an initial examination of this hypothesis, we have ex- 
amined the biochemical basis for the effects of the parent compound of this series 
(ara-tubercidin; Fig. 1) on the inhibition of viral DNA replication by herpes sim- 
plex viruses. 
KB cells, an established human cell line derived from an epidermoid oral car- 
cinoma, were used to propagate HSV-1 and HSV-2. Cells were routinely passaged 
in minimal essential medium (MEM) with Hank’s salts supplemented with 10% 
calf serum. Monolayer cultures of cells were grown to confluency in 25cm2 flasks 
and used for virus titer (yield) reduction experiments as follows. Cultures were in- 
fected with the HF strain of HSV-1 (obtained from Dr. G.H. Cohen, University 
of Pennsylvania) at a multiplicity of infection of 5 PFUlcell in MEM containing 
Earle’s salts buffered with 25 mM Hepes and supplemented with 5% serum and 
0.127 g/l L-arginine (virus growth medium (VGM)). Following a l-h incubation to 
99 
permit virus adsorption, selected concentrations of ara-tubercidin in VGM were 
added and the cultures incubated for 18-24 h at 37°C. The amount of infectious 
virus produced was quantitated as described previously (Shipman et al., 1976). Ara- 
tubercidin and its 5’-monophosphate were synthesized by one of us (P.D.C.) as 
described elsewhere (Cook, 1982). The monophosphate was converted to its S- 
triphosphate by the general method of Hoard and Ott (1965). 
The results of titer reduction assays with HSV-1 indicated that production of in- 
fectious virus was inhibited by ara-tubercidin, albeit weakly. Individual Iso con- 
centrations of 620 PM (Turk et al., 1987) and 730 FM were obtained in two sep- 
arate experiments. Similarly, in a plaque reduction assay an 15,-, concentration of 
320 l.r,M was obtained (Turk et al., 1987). In contrast, the known antiviral drug 
vidarabine (ara-A) (Buchanan and Hess, 1980) had an Iso concentration of 2.1 ~J,M 
when assayed in the presence of an adenosine deaminase inhibitor (Schwartz et 
al., 1976). Thus, changing the purine ring system of vidarabine to the pyrrolo[2,3- 
d]-pyrimidine ring system of ara-tubercidin decreased activity against HSV-1 >300- 
fold. 
In an effort to elucidate the biochemical basis for the antiviral effect of ara-tub- 
ercidin, inhibition of cellular and viral DNA replication was examined as part of 
the titer reduction experiment which gave an Iso concentration of 620 PM. In that 
experiment [3H]dThd (24 Ci/mmol) was added to the cultures at a final concen- 
tration of 6 ~J,M (2 @X/ml) concurrently with the test compound. After incubation 
and subsequent titration of virus, cells were harvested and viral DNA separated 
from cellular DNA by isopycnic centrifugation in CsCl gradients as previously de- 
scribed (Shipman et al., 1976). The results (not shown) indicated a modest pref- 
erential inhibition of HSV-1 DNA synthesis with respect to cellular DNA synthe- 
sis within the same infected cells. A comparison of Isa concentrations, for instance, 
indicated that viral DNA synthesis was 3-fold more sensitive to inhibition than was 
the synthesis of cellular DNA (I,, concentrations = 220 FM (Turk et al., 1987) 
and 670 PM, respectively). This 3-fold difference in sensitivity, while not large, is 
nearly identical in magnitude to that reported by Zerial et al. (1986) for a carbo- 
cyclic arabinosyl analog of 7-deazaguanosine, and by Schwartz et al. (1976) for the 
clinically useful drug vidarabine. 
The mechanistic basis for the differential inhibition of viral and cellular DNA 
synthesis was investigated by measuring the effect of the S-triphosphate of ara- 
tubercidin (ara-tubercidin-TP) on partially purified DNA polymerases. The viral 
DNA polymerases specified by HSV-1 and HSV-2 and cellular DNA polymerases 
(Y and p were isolated and assayed as described previously (Bennett et al., 1981; 
Reinke et al., 1978). Table 1 lists the inhibitory constants determined for ara-tub- 
ercidin-TP and illustrates that this compound was an effective inhibitor of the viral 
polymerases., To our knowledge, this is the first report of a herpesvirus DNA po- 
lymerase being inhibited by a pyrrolopyrimidine nucleotide. Furthermore, this 
compound selectively inhibited HSV-1 and HSV-2 polymerases with respect to 
cellular polymerases. Based on a comparison of Ki concentrations, cellular poly- 
merase (Y had approx. 5- and 15-fold less affinity for this inhibitor than did the re- 
spective viral polymerases. Cellular polymerase l3 was not inhibited significantly 
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TABLE 1 
Kinetic constants for inhibition of HSV-induced and .cellular DNA polymerases by ara-tubercidin 5’- 
triphosphate’. 





* Viral DNA polymerases were isolated from KB cells infected with either the HF strain of HSV-1 or 
the X-79 strain of HSV-2. Cellular DNA polymerases CY and f3 were isolated from uninfected KB 
cells. Polymerase activity was measured by quantitating the amount of [“H]dATP incorporated into 
acid-insoluble material during a 15-min incubation of the enzyme preparation with the appropriate 
reaction mixture. Ki concentrations were determined from analysis of Dixon plots (Dixon and Webb, 
1979). 
by this compound at the highest concentration tested. The preferential inhibition 
of viral DNA synthesis by ara-tubercidin therefore is a possible consequence of 
the preferential sensitivity of the viral DNA polymerase to ara-tubercidin-TP. 
The manner in which viral DNA polymerases were inhibited by ara-tubercidin- 
TP was investigated further using two different methods. (1) Analysis of kinetic 
data from inhibition studies with partially purified enzymes (data not shown) in- 
dicated that (a) inhibition of HSV-1 and HSV-2 polymerases was competitive with 
respect to dATP, and (b) inhibition of the HSV-2 enzyme was noncompetitive with 
respect to dTTP. The Ki concentration calculated from a Dixon plot of these data 
was 40 FM. (2) Viral DNA synthesis also was measured in nuclei isolated from 
HSV-2 infected cells. We previously have shown that this system provides a con- 
venient in situ source of herpes DNA polymerase under conditions in which the 
natural replication complex remains intact (Barnett et al., 1984). In brief, mono- 
layer cultures of KB cells were infected with the X-79 strain of HSV-2 (obtained 
from Dr. E.R. Kern, University of Utah) at a multiplicity of infection of 2 PFU/cell 
and harvested 9 h post-infection (Barnett et al., 1984). Nuclei were isolated and 
DNA synthesis measured by quantitating the amount of [3H]dATP incorporated 
into acid-insoluble material. The Dixon plot presented in Fig. 2 confirms results 
obtained with partially purified enzymes by illustrating that inhibition of HSV-2 
DNA polymerase activity by ara-tubercidin-TP was competitive with respect to 
dATP. The average ZCi concentration of ara-tubercidin-TP derived from two ex- 
periments was 16 p,M and was similar in magnitude to the value (5 p.M) obtained 
using the partially purified enzyme. In contrast, we previously reported that the 
S-triphosphate of vidarabine had a ZCi concentration of 0.03 FM in this system 
(Barnett et al., 1984). The >500-fold difference in potency is similar to that noted 
above in HSV-1 titer reduction experiments with these two compounds and fur- 
ther implicates the viral DNA polymerase as possessing a significant role in the 
antiviral activity of ara-tubercidin. 
The results reported herein suggest additional studies which should be per- 
formed. For example, we have not eliminated the possibility that ara-tubercidin- 
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Fig. 2. Dixon plot of the inhibition by am-tubercidin S-triphosphate of viral DNA synthesis in nuclei 
isolated from HSV-24nfected KB cells. Reaction mixtures included one of the three [)H]dATP con- 
centrations indicated. The common intersection of the regression lines above the s-axis indicates that 
inhibition is either competitive or mked-type in manner (Dixon and Webb, 1979). A replot of the slopes 
(inset) passes through the origin, indicating that inhibition is competitive rather than mixed-type (Dixon 
and Webb, 1979). 
TP acted as an alternate substrate which slowed elongation by the viral DNA po- 
lymerases. Furthermore, the hypothesis that inhibition of viral DNA polymerase 
accounted for the antiviral activity of ara-tubercidin is based on the assumption 
that ara-tubercidin was phosphorylated in situ to the active triphosphate metabo- 
lite. The fact that the I,, concentration of the nucleoside for inhibition of virus 
replication was significantly higher than the Ki concentration of the triphosphate 
for inhibition of viral DNA polymerase activity suggests that ara-tubercidin might 
be poorly phosphorylated in vitro. These and other questions must be answered 
before the mode of action of this nucleoside can be understood completely. 
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